CMP Pharma provides a wealth of experience in the formulation of proprietary topicals and oral liquids for niche markets within the pharmaceutical and life science industries. We combine this formulation experience with decades of manufacturing experience and a low-cost manufacturing base to provide high quality and value to both patients and our customers. CMP Pharma focuses on developing niche products where needs for alternative dosage forms exist in the acute and long-term care setting.
CMP Pharma was founded by Henry Smith as Carolina Medical Products Company in 1975 while he was a professor of drug manufacturing at the University of North Carolina at Chapel Hill’s School of Pharmacy. In 1982, FDA granted Carolina Medical an approval for Sodium Polystyrene Sulfonate Suspension (SPS® Suspension) for the treatment of hyperkalemia. Prior to this, sodium polystyrene sulfonate was only available as a powder “for suspension”.
Another innovative liquid approval followed for Isoniazid Oral Solution, USP, the only FDA approved liquid treatment for tuberculosis.
Most recently CMP received approval of an NDA for Spironolactone Oral Suspension (CaroSpir®) developed specifically for patients who have difficulty swallowing and are suffering from heart failure, edema caused by heart failure and cirrhosis, and hypertension.
We’ve manufactured high-quality pharmaceutical products at our Farmville, North Carolina facility since 1986.